REFERENCES
- Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team [see comments]. New Engl J Med. 1999;341(25):1865–1873.
- Staszewski S. Update on study 006 — EFV + AZT + 3TC versus the current "standard of care" IDV + AZT + 3TC. Int J Clin Pract. 1999;103(suppl):10–15.
- Nevirapine package insert. Roxane Laboratories, Inc., Co-lumbus Ohio, 2000.
- Calabrese LH, Mawhorter SD, Podlipsky K, et al. Immune activation and HIV infection. Relationship to treatment and viral load. Fourth Conference on Retroviruses and Oppor-tunistic Infections; 1997; Washington, DC.
- Bouscarat F, Levacher-Clergeot M, Dazza MC, et al. Corre-lation on CD8 lymphocyte activation with cellular viremia and plasma HIV RNA levels in asymptomatic patients in-fected by human immunodeficiency virus type 1. AIDS Res Human Retroviruses. 1996;12:17–24.
- Liu Z, Cumberland WG, Hultin LE, Prince HE, Detels R, Giorgi JV. Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multi Center AIDS Cohort Study than CD4+ cell count, soluble immune acti-vation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Human Retrovirol. 1997;16:83–92.
- Katlama C. Managing HIV infection. Two new aspects. Presse Medicale. 1999;28\(suppl 3):11–14.
- Ruiz N. Clinical history of efavirenz [review]. Int J Clin Pract. 1999;103(suppl):3–7.
- Katlama C. Review of NNRTIs: "Today and tomorrow" [review]. Int J Clin Pract. 1999;103(suppl):16–20.
- Moyle G. Efavirenz: Practicalities, considerations and new issues [review]. Int J Clin Pract. 1999;103(suppl):30–34.
- Tashima KT, Caliendo AM, Ahmad M, et al. Cerebrospinal fluid in human immunodeficiency virus type 1 (HIV-1) sup-pression and efavirenz drug concentrations in HIV-1-in-fected patients receiving combination therapy. J Infect Dis. 1999;180(3):862–864.